JUPITER, Fla., March 4, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb, will be making a presentation at the World Biofuels Markets exhibition at the Beurs-World Trade Center in Rotterdam, The Netherlands during its Advanced Biofuels Session: Transformative Technologies, at 4:00 p.m. local time on March 13, 2013. (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ) All attendees of the World Biofuels Markets are welcome to visit Dyadic's stand located at Booth #E506 where Dyadic's leading scientists will be available to discuss specific applications of Dyadic's AlternaFuel ® CMAX™ biofuels enzymes. The World Biofuels Markets is Europe's largest biofuels congress and exhibition and one of the industry's premier events, supporting the world's development and search for alternative energy sources. About Dyadic Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.